WST DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WST

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased West common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - Specific claims include that West was experiencing significant destocking in its high-margin products, which contradicted its public statements about strong customer demand [5]. - The lawsuit also highlights operational inefficiencies in the SmartDose device that negatively impacted profit margins and led to potential restructuring activities [5].